Answers are grounded in this paper and cite their sources.
Background: Hepatotoxicity is an adverse effect that may limit the clinical use of capecitabine (CAP). The present study compared the protective effects of thiamine pyrophosphate (TPP) and thiamine against CAP-induced liver injury in rats. Methods: Twenty-four albino Wistar rats were randomly assigned to four groups (n = 6 per group): healthy control (HG), CAP-treated (CP), TPP + CAP (TPCP), and thiamine + CAP (TCP). The TCP and TPCP groups received thiamine and TPP (20 mg/kg, intraperitoneally), respectively, while the HG and CP groups received 0.9% sodium chloride (NaCl) by oral gavage. Treatments were administered daily, and CAP (200 mg/kg, orally) was given 5 days weekly for 28 days. Hepatic oxidative stress and inflammatory markers, along with serum Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) activities, were measured. Histopathological injury and the immunoreactivities of cytokines and 8-hydroxy-2′-deoxyguanosine (8-OHdG) were also evaluated. Results: Compared with HG, CAP increased hepatic MDA and proinflammatory cytokine levels and serum ALT and AST activities, while decreasing tGSH, SOD, and CAT levels (all p < 0.001). TPP attenuated these biochemical alterations more effectively than thiamine (p < 0.001). TPP and thiamine reduced necrosis and hydropic degeneration, and decreased IL-1β, IL-6, TNF-α, and 8-OHdG immunopositivity compared with the CP group (p < 0.001). TPP reduced hepatic immunopositivity more effectively than thiamine (p < 0.001). Conclusions: Under the tested dosing conditions, TPP provided greater hepatoprotection than thiamine against CAP-induced liver injury in rats; however, further studies are needed to establish its clinical relevance.
No takes yet. Share an insight, caveat, or question.
Süleyman et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: